DCGI Approves QDENGA: India's First Dengue Vaccine for Ages 4 to 60

The Drug Controller General of India (DCGI) has granted market authorization for QDENGA (TAK-003), India's first approved dengue vaccine. Developed by Japanese pharmaceutical major Takeda, the tetravalent live-attenuated vaccine is cleared for individuals aged 4 to 60 years. Administered in two doses three months apart, QDENGA protects against all four dengue virus serotypes without requiring mandatory pre-vaccination blood testing. This milestone addresses a major national health challenge, as India accounts for roughly one-third of the total global dengue burden.

What Happened

The Drug Controller General of India (DCGI) granted official market authorisation for Takeda's dengue vaccine QDENGA (TAK-003) under Form CT-20 of the New Drugs and Clinical Trials (NDCT) Rules, 2019. The decision enables the commercial deployment of India's first dengue vaccine for individuals aged 4 to 60 years. The approval was backed by global trial data and the domestic Phase III DEN-302 clinical study conducted across Indian centers.

When & Where

The market authorisation was officially announced in July 2026 in New Delhi by the Central Drugs Standard Control Organisation (CDSCO). Commercial availability in Indian healthcare facilities is targeted for launch following regulatory rollout planning and distribution arrangements.

Who Is Involved

Takeda Biopharmaceuticals: Japanese pharmaceutical company and primary developer of TAK-003.
DCGI / CDSCO: India's primary drug regulator operating under the Ministry of Health and Family Welfare.
Biological E Limited: Hyderabad-based Indian firm partnering with Takeda for local vaccine manufacturing.
World Health Organization (WHO): Issued prequalification and recommendation via its Strategic Advisory Group of Experts (SAGE).

How It Works

Genetic Design: Uses a weakened live Dengue Serotype 2 (DENV-2) virus as the genetic backbone.
Chimeric Engineering: Surface proteins of serotypes DENV-1, DENV-3, and DENV-4 are grafted onto the DENV-2 backbone.
Immune Response: Triggers robust neutralising antibodies and T-cell responses against all four circulating dengue serotypes.
Administration: Injected subcutaneously in a two-dose schedule spaced three months apart (Month 0 and Month 3).

Why It Matters

Public Health Impact: Significantly reduces severe dengue hemorrhagic fever and hospitalization rates during seasonal monsoon surges.
Economic Relief: Alleviates out-of-pocket medical expenditure and hospital bed overload in urban centers.
Syllabus Linkage: Relevant to UPSC GS Paper 2 (Public Health & Governance) and GS Paper 3 (Biotechnology & Intellectual Property).

Historical Background

📌 [BACKGROUND — verify independently]

1943: Dengue virus was first isolated by Japanese scientists Ren Kimura and Susumu Hotta during World War II.
2015: Dengvaxia (Sanofi Pasteur) became the world's first licensed dengue vaccine, though restricted to individuals with proven prior infection due to safety risks in dengue-naïve people.
2022: QDENGA secured its first major international regulatory approval from the European Medicines Agency (EMA).

Previous Related Events

📌 [BACKGROUND — verify independently]

December 2022: European Medicines Agency (EMA) granted marketing authorization for QDENGA for ages 4 and above.
October 2023: WHO Strategic Advisory Group of Experts (SAGE) formally recommended QDENGA in high-transmission settings.
May 2024: WHO granted prequalification status to QDENGA, enabling international procurement by UNICEF and PAHO.

Static GK Connection

Aedes aegypti: The primary day-biting mosquito vector responsible for transmitting the dengue Flavivirus, also carrying Zika and Chikungunya.
Drugs and Cosmetics Act, 1940: The primary statutory framework governing drug approvals, clinical trials, and market authorisations in India.

India & World Comparison

India accounts for nearly 33% of global dengue infections, with reported annual cases rising over elevenfold in twenty years. QDENGA is already approved in over 43 countries, including Indonesia, Brazil, and Argentina, where it is incorporated into national immunization programs.

Future Impact

Local production by Biological E in Hyderabad aims to produce 50 million doses annually to ensure domestic supply and export affordability.
Potential inclusion in India's Universal Immunization Programme (UIP) following health economics evaluations.
Takeda aims to reach global manufacturing capability of 100 million doses per year by 2030.

🔑 Key Points for Revision

Vaccine Identity: QDENGA (TAK-003) is India's first DCGI-approved dengue vaccine.
Target Demographic: Approved for age band 4 to 60 years.
No Pre-Testing: Administered regardless of prior dengue exposure status without mandatory pre-screening.
Dosage Schedule: 2 subcutaneous doses given 3 months apart.
Platform: Live-attenuated tetravalent vaccine covering serotypes DENV-1, DENV-2, DENV-3, and DENV-4.
Backbone Virus: Built upon a genetically modified Dengue serotype 2 (DENV-2) virus structure.
Regulatory Body: Central Drugs Standard Control Organisation (CDSCO) led by DCGI.
Legal Rule: Approved under Form CT-20 of New Drugs and Clinical Trials Rules, 2019.
Efficacy Stat: 80.2% efficacy against symptomatic dengue at 12 months post-second dose.
Hospitalisation Protection: 90.4% reduction in dengue hospitalisation at 18 months.
Indian Trial: Phase III DEN-302 trial evaluated safety and immunogenicity in Indian participants.
Global Trial: Phase III TIDES study involved over 20,000 children across 8 endemic countries.
WHO Status: Holds WHO Prequalification status granted in May 2024.
Manufacturing Partner: Biological E Limited (Hyderabad) contracted for domestic production.
Disease Vector: Transmitted by female Aedes aegypti and Aedes albopictus mosquitoes.

🧠 Concept Link (Static GK Deep Dive)

Core Concept: Central Drugs Standard Control Organisation (CDSCO) & Vaccine Regulation

Definition: CDSCO is India's national regulatory authority for pharmaceuticals, medical devices, and clinical trials.
Constitutional / Legal Basis: Derives statutory authority from the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.
Scientific / Economic Principle: Evaluates safety, efficacy, and quality control through phased clinical trials before granting market authorization.
How it connects to this event: CDSCO's chief official, the DCGI, evaluated Phase III trial data to grant market approval (Form CT-20) for QDENGA under NDCT Rules 2019.
Origin & History: Statutory body established under the Ministry of Health and Family Welfare pursuant to the 1940 legislation.
Key milestone 1: Enactment of the New Drugs and Clinical Trials (NDCT) Rules in 2019 to streamline clinical trial approvals and market clearances.
Key milestone 2: Granting Emergency Use Authorisations (EUA) for indigenous COVID-19 vaccines (Covaxin and Covishield) during 2020–2021.
Related Acts / Schemes / Treaties: National Health Policy 2017, Biological Weapons Convention, and Good Manufacturing Practice (GMP) guidelines.
Nodal Ministry / Body: Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare.
India-specific relevance: Ensures life-saving biological products sold in India meet strict global standards for purity and clinical safety.
Global comparison: Performs functions equivalent to the US Food and Drug Administration (US FDA) and European Medicines Agency (EMA).
Data Point: CDSCO regulates a domestic pharmaceutical industry valued at over $50 billion as of 2024.
Common exam angle: UPSC frequently tests the distinction between statutory drug authorities (CDSCO/DCGI) and policy research bodies (ICMR).
Easy memory hook: C-D-S-C-O = Central Drug Safety Control Office (headed by DCGI).

❓ Practice MCQs

Q1. Which regulatory authority in India granted market authorization for the dengue vaccine QDENGA? [Easy]

A) Indian Council of Medical Research (ICMR)

B) Drug Controller General of India (DCGI)

C) National Medical Commission (NMC)

D) Food Safety and Standards Authority of India (FSSAI)

Answer: B

Explanation: The Drug Controller General of India (DCGI), who heads CDSCO, granted market authorization for QDENGA under the NDCT Rules, 2019.

Q2. What is the approved age range for administering the QDENGA dengue vaccine in India? [Easy]

A) 1 to 18 years

B) 4 to 60 years

C) 18 to 45 years

D) 60 years and above

Answer: B

Explanation: The DCGI approved QDENGA specifically for individuals aged 4 to 60 years.

Q3. What type of vaccine platform is used in Takeda's QDENGA (TAK-003)? [Moderate]

A) mRNA vaccine

B) Inactivated viral vaccine

C) Live-attenuated tetravalent vaccine

D) Recombinant protein subunit vaccine

Answer: C

Explanation: QDENGA is a live-attenuated tetravalent vaccine engineered to protect against all four dengue virus serotypes.

Q4. Under which specific rule framework was the approval for QDENGA issued by the DCGI? [Moderate]

A) Epidemic Diseases Act Rules, 1897

B) New Drugs and Clinical Trials (NDCT) Rules, 2019

C) Pharmacy Act Regulations, 1948

D) Medical Devices Rules, 2017

Answer: B

Explanation: Market authorisation was granted under Form CT-20 of the New Drugs and Clinical Trials (NDCT) Rules, 2019.

Q5. How does QDENGA differ significantly from earlier generation dengue vaccines like Dengvaxia? [Moderate]

A) It is an oral vaccine rather than an injectable.

B) It requires four separate doses over two years.

C) It can be given without requiring pre-vaccination screening for past infection.

D) It only targets Dengue serotype 1.

Answer: C

Explanation: Unlike Dengvaxia, QDENGA can be administered without prior blood testing to verify past dengue exposure.

Q6. Which specific viral strain serves as the genetic backbone for the chimeric construction of QDENGA? [Tricky]

A) Dengue Serotype 1 (DENV-1)

B) Dengue Serotype 2 (DENV-2)

C) Yellow Fever virus

D) Zika virus

Answer: B

Explanation: QDENGA is built on a live-attenuated Dengue Serotype 2 (DENV-2) genetic backbone into which genes from serotypes 1, 3, and 4 are inserted.

Q7. What is the administration schedule and dosage route for QDENGA approved in India? [Tricky]

A) Single intramusclar dose of 1.0 mL

B) Two subcutaneous doses of 0.5 mL given 3 months apart

C) Three oral doses given at 0, 1, and 6 months

D) Two intradermal doses given 14 days apart

Answer: B

Explanation: QDENGA is administered subcutaneously in a 0.5 mL two-dose regimen spaced three months apart.

Q8. Which Indian pharmaceutical firm has partnered with Takeda to manufacture QDENGA locally? [Tricky]

A) Serum Institute of India, Pune

B) Bharat Biotech, Hyderabad

C) Biological E Limited, Hyderabad

D) Dr. Reddy's Laboratories, Hyderabad

Answer: C

Explanation: Takeda partnered with Hyderabad-based Biological E Limited to manufacture up to 50 million doses of QDENGA annually in India.

📜 Previous Year Question Style (PYQ)

PYQ 1:

With reference to mosquito-borne viral diseases in India, consider the following statements regarding Dengue:

1. Dengue is caused by a single, unique viral serotype.
2. The primary mosquito vector for dengue transmission is Aedes aegypti.

Which of the statements given above is/are correct?

A) 1 only

B) 2 only

C) Both 1 and 2

D) Neither 1 nor 2

Answer: B

Explanation: Statement 1 is incorrect because dengue is caused by four distinct virus serotypes (DENV-1, DENV-2, DENV-3, and DENV-4). Statement 2 is correct as Aedes aegypti is the primary vector.

PYQ 2:

Consider the following statements regarding the newly approved dengue vaccine QDENGA (TAK-003):

1. It is a live-attenuated tetravalent vaccine that targets all four dengue serotypes.
2. Pre-vaccination blood testing to confirm prior infection is mandatory before administering the vaccine.
3. The vaccine is approved for individuals aged 4 to 60 years in India.

Which of the above statements are correct?

A) 1 and 2 only

B) 2 and 3 only

C) 1 and 3 only

D) 1, 2, and 3

Answer: C

Explanation: Statements 1 and 3 are correct. Statement 2 is incorrect because QDENGA can be administered regardless of prior dengue exposure, eliminating the need for pre-vaccination screening.

PYQ 3:

Match List-I (Vaccine/Drug Term) with List-II (Biological Characteristic):

List-I:

a. Live-attenuated vaccine b. Tetravalent vaccine c. Chimeric virus d. Serotype

List-II:

1. Targets four distinct strains of a pathogen
2. Uses weakened live pathogens to trigger immunity
3. Hybrid virus created by combining genes from different viruses
4. Variation within a species of virus based on surface antigens

Select the correct answer using the code given below:

A) a-2, b-1, c-3, d-4

B) a-1, b-2, c-4, d-3

C) a-2, b-4, c-3, d-1

D) a-3, b-1, c-2, d-4

Answer: A

Explanation: Live-attenuated uses weakened pathogens (a-2); tetravalent targets four strains (b-1); chimeric combines genetic material from different strains (c-3); serotype refers to antigenic variations (d-4).

✍️ Mains Answer Pointers

Question 1 (150 words): Discuss the public health significance of DCGI's approval of the QDENGA vaccine in managing India's seasonal dengue burden.

The approval of QDENGA (TAK-003) by the Drug Controller General of India on July 20, 2026, marks a pivotal shift in India's fight against vector-borne diseases. Accounting for nearly one-third of the global dengue burden, India faces recurring seasonal outbreaks that severely strain healthcare infrastructure.

QDENGA's major public health value lies in its live-attenuated tetravalent design that protects against all four circulating dengue serotypes for individuals aged 4 to 60 years. Unlike previous vaccine candidates, QDENGA does not require mandatory pre-vaccination screening, making large-scale deployment feasible in resource-constrained public health settings. Clinical trials show a 90.4% reduction in hospitalizations, which will significantly reduce ICU overload and out-of-pocket medical expenses for households.

However, vaccination must complement, rather than replace, traditional vector management, urban sanitation, and disease surveillance under the National Vector Borne Disease Control Programme.

Question 2 (250 words): Analyze the challenges in implementing a national vaccination campaign against dengue in India and suggest strategic measures for effective rollout.

India's approval of Takeda's QDENGA vaccine introduces a potent preventative tool against a disease whose reported incidence has increased elevenfold over two decades. While the approval under the New Drugs and Clinical Trials Rules, 2019, is a breakthrough, nationwide rollout presents complex policy, economic, and logistical challenges.

First, economic accessibility remains a key bottleneck. If QDENGA remains confined to private healthcare markets, equitable access for vulnerable socio-economic groups will be limited. Second, manufacturing supply chains must scale rapidly; Takeda's domestic partnership with Biological E to produce 50 million doses annually is vital but requires sustained momentum. Third, variable efficacy across different dengue serotypes—particularly in individuals without prior exposure—necessitates continuous post-marketing surveillance and pharmacovigilance.

To ensure an effective national strategy, India should pursue a multi-pronged approach:

Phased Integration: Prioritize high-endemic urban hotspots and districts with high hospitalisation rates before universal scaling.
Price Regulation & UIP Entry: Include the vaccine within the Universal Immunization Programme (UIP) or subsidize procurement through tiered pricing models.
Integrated Vector Management: Maintain robust municipal vector control, source reduction, and community awareness, as vaccination alone cannot eliminate transmission.
Real-time Surveillance: Strengthen digital tracking through platforms like U-WIN to monitor coverage, booster requirements, and adverse events.

Combining vaccine technology with systemic urban sanitation will prove decisive in curbing India's dengue epidemic.

⚠️ Examiner Trap

Trap 1: Students often confuse QDENGA (TAK-003) with Dengvaxia. The correct fact is that Dengvaxia required mandatory blood testing to prove prior infection, whereas QDENGA is approved without pre-vaccination screening.
Trap 2: A common wrong assumption is that QDENGA covers only adults. The reality is that the DCGI approved it for individuals aged 4 to 60 years.
Trap 3: Many students miss the regulatory authority details. Always remember that drug and vaccine approvals are granted by the DCGI under CDSCO, not by the Indian Council of Medical Research (ICMR).

🧭 Exam Tip

Prelims Focus: Focus on specific factual details such as the vaccine platform (live-attenuated tetravalent), target age group (4–60 years), lack of pre-screening requirement, two-dose schedule (3 months apart), and the governing regulatory rule (NDCT Rules 2019).
Mains Focus: Frame answers around public health governance, health economics (reducing out-of-pocket expenditure), biotechnology, and the necessity of integrating vaccination with vector control under the National Vector Borne Disease Control Programme.
Interview Angle: Be prepared to discuss whether dengue vaccines should be included in the public Universal Immunization Programme (UIP) versus remaining in the private market, balancing fiscal constraints against public health benefits.
High-Probability Prediction: Expect a statement-based question in Prelims comparing live-attenuated versus mRNA/subunit vaccine platforms, or asking about vector-borne disease control initiatives in India.

DCGI Approves QDENGA: India's First Dengue Vaccine for Ages 4 to 60

What Happened

When & Where

Who Is Involved

Takeda Biopharmaceuticals: Japanese pharmaceutical company and primary developer of TAK-003.
DCGI / CDSCO: India's primary drug regulator operating under the Ministry of Health and Family Welfare.
Biological E Limited: Hyderabad-based Indian firm partnering with Takeda for local vaccine manufacturing.
World Health Organization (WHO): Issued prequalification and recommendation via its Strategic Advisory Group of Experts (SAGE).

How It Works

Genetic Design: Uses a weakened live Dengue Serotype 2 (DENV-2) virus as the genetic backbone.
Chimeric Engineering: Surface proteins of serotypes DENV-1, DENV-3, and DENV-4 are grafted onto the DENV-2 backbone.
Immune Response: Triggers robust neutralising antibodies and T-cell responses against all four circulating dengue serotypes.
Administration: Injected subcutaneously in a two-dose schedule spaced three months apart (Month 0 and Month 3).

Why It Matters

Public Health Impact: Significantly reduces severe dengue hemorrhagic fever and hospitalization rates during seasonal monsoon surges.
Economic Relief: Alleviates out-of-pocket medical expenditure and hospital bed overload in urban centers.
Syllabus Linkage: Relevant to UPSC GS Paper 2 (Public Health & Governance) and GS Paper 3 (Biotechnology & Intellectual Property).

Historical Background

📌 [BACKGROUND — verify independently]

1943: Dengue virus was first isolated by Japanese scientists Ren Kimura and Susumu Hotta during World War II.
2015: Dengvaxia (Sanofi Pasteur) became the world's first licensed dengue vaccine, though restricted to individuals with proven prior infection due to safety risks in dengue-naïve people.
2022: QDENGA secured its first major international regulatory approval from the European Medicines Agency (EMA).

Previous Related Events

📌 [BACKGROUND — verify independently]

December 2022: European Medicines Agency (EMA) granted marketing authorization for QDENGA for ages 4 and above.
October 2023: WHO Strategic Advisory Group of Experts (SAGE) formally recommended QDENGA in high-transmission settings.
May 2024: WHO granted prequalification status to QDENGA, enabling international procurement by UNICEF and PAHO.

Static GK Connection

Aedes aegypti: The primary day-biting mosquito vector responsible for transmitting the dengue Flavivirus, also carrying Zika and Chikungunya.
Drugs and Cosmetics Act, 1940: The primary statutory framework governing drug approvals, clinical trials, and market authorisations in India.

India & World Comparison

Future Impact

Local production by Biological E in Hyderabad aims to produce 50 million doses annually to ensure domestic supply and export affordability.
Potential inclusion in India's Universal Immunization Programme (UIP) following health economics evaluations.
Takeda aims to reach global manufacturing capability of 100 million doses per year by 2030.

🔑 Key Points for Revision

Vaccine Identity: QDENGA (TAK-003) is India's first DCGI-approved dengue vaccine.
Target Demographic: Approved for age band 4 to 60 years.
No Pre-Testing: Administered regardless of prior dengue exposure status without mandatory pre-screening.
Dosage Schedule: 2 subcutaneous doses given 3 months apart.
Platform: Live-attenuated tetravalent vaccine covering serotypes DENV-1, DENV-2, DENV-3, and DENV-4.
Backbone Virus: Built upon a genetically modified Dengue serotype 2 (DENV-2) virus structure.
Regulatory Body: Central Drugs Standard Control Organisation (CDSCO) led by DCGI.
Legal Rule: Approved under Form CT-20 of New Drugs and Clinical Trials Rules, 2019.
Efficacy Stat: 80.2% efficacy against symptomatic dengue at 12 months post-second dose.
Hospitalisation Protection: 90.4% reduction in dengue hospitalisation at 18 months.
Indian Trial: Phase III DEN-302 trial evaluated safety and immunogenicity in Indian participants.
Global Trial: Phase III TIDES study involved over 20,000 children across 8 endemic countries.
WHO Status: Holds WHO Prequalification status granted in May 2024.
Manufacturing Partner: Biological E Limited (Hyderabad) contracted for domestic production.
Disease Vector: Transmitted by female Aedes aegypti and Aedes albopictus mosquitoes.

🧠 Concept Link (Static GK Deep Dive)

Core Concept: Central Drugs Standard Control Organisation (CDSCO) & Vaccine Regulation

Definition: CDSCO is India's national regulatory authority for pharmaceuticals, medical devices, and clinical trials.
Constitutional / Legal Basis: Derives statutory authority from the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945.
Scientific / Economic Principle: Evaluates safety, efficacy, and quality control through phased clinical trials before granting market authorization.
How it connects to this event: CDSCO's chief official, the DCGI, evaluated Phase III trial data to grant market approval (Form CT-20) for QDENGA under NDCT Rules 2019.
Origin & History: Statutory body established under the Ministry of Health and Family Welfare pursuant to the 1940 legislation.
Key milestone 1: Enactment of the New Drugs and Clinical Trials (NDCT) Rules in 2019 to streamline clinical trial approvals and market clearances.
Key milestone 2: Granting Emergency Use Authorisations (EUA) for indigenous COVID-19 vaccines (Covaxin and Covishield) during 2020–2021.
Related Acts / Schemes / Treaties: National Health Policy 2017, Biological Weapons Convention, and Good Manufacturing Practice (GMP) guidelines.
Nodal Ministry / Body: Directorate General of Health Services (DGHS), Ministry of Health and Family Welfare.
India-specific relevance: Ensures life-saving biological products sold in India meet strict global standards for purity and clinical safety.
Global comparison: Performs functions equivalent to the US Food and Drug Administration (US FDA) and European Medicines Agency (EMA).
Data Point: CDSCO regulates a domestic pharmaceutical industry valued at over $50 billion as of 2024.
Common exam angle: UPSC frequently tests the distinction between statutory drug authorities (CDSCO/DCGI) and policy research bodies (ICMR).
Easy memory hook: C-D-S-C-O = Central Drug Safety Control Office (headed by DCGI).

❓ Practice MCQs

Q1. Which regulatory authority in India granted market authorization for the dengue vaccine QDENGA? [Easy]

A) Indian Council of Medical Research (ICMR)

B) Drug Controller General of India (DCGI)

C) National Medical Commission (NMC)

D) Food Safety and Standards Authority of India (FSSAI)

Answer: B

Explanation: The Drug Controller General of India (DCGI), who heads CDSCO, granted market authorization for QDENGA under the NDCT Rules, 2019.

Q2. What is the approved age range for administering the QDENGA dengue vaccine in India? [Easy]

A) 1 to 18 years

B) 4 to 60 years

C) 18 to 45 years

D) 60 years and above

Answer: B

Explanation: The DCGI approved QDENGA specifically for individuals aged 4 to 60 years.

Q3. What type of vaccine platform is used in Takeda's QDENGA (TAK-003)? [Moderate]

A) mRNA vaccine

B) Inactivated viral vaccine

C) Live-attenuated tetravalent vaccine

D) Recombinant protein subunit vaccine

Answer: C

Explanation: QDENGA is a live-attenuated tetravalent vaccine engineered to protect against all four dengue virus serotypes.

Q4. Under which specific rule framework was the approval for QDENGA issued by the DCGI? [Moderate]

A) Epidemic Diseases Act Rules, 1897

B) New Drugs and Clinical Trials (NDCT) Rules, 2019

C) Pharmacy Act Regulations, 1948

D) Medical Devices Rules, 2017

Answer: B

Explanation: Market authorisation was granted under Form CT-20 of the New Drugs and Clinical Trials (NDCT) Rules, 2019.

Q5. How does QDENGA differ significantly from earlier generation dengue vaccines like Dengvaxia? [Moderate]

A) It is an oral vaccine rather than an injectable.

B) It requires four separate doses over two years.

C) It can be given without requiring pre-vaccination screening for past infection.

D) It only targets Dengue serotype 1.

Answer: C

Explanation: Unlike Dengvaxia, QDENGA can be administered without prior blood testing to verify past dengue exposure.

Q6. Which specific viral strain serves as the genetic backbone for the chimeric construction of QDENGA? [Tricky]

A) Dengue Serotype 1 (DENV-1)

B) Dengue Serotype 2 (DENV-2)

C) Yellow Fever virus

D) Zika virus

Answer: B

Explanation: QDENGA is built on a live-attenuated Dengue Serotype 2 (DENV-2) genetic backbone into which genes from serotypes 1, 3, and 4 are inserted.

Q7. What is the administration schedule and dosage route for QDENGA approved in India? [Tricky]

A) Single intramusclar dose of 1.0 mL

B) Two subcutaneous doses of 0.5 mL given 3 months apart

C) Three oral doses given at 0, 1, and 6 months

D) Two intradermal doses given 14 days apart

Answer: B

Explanation: QDENGA is administered subcutaneously in a 0.5 mL two-dose regimen spaced three months apart.

Q8. Which Indian pharmaceutical firm has partnered with Takeda to manufacture QDENGA locally? [Tricky]

A) Serum Institute of India, Pune

B) Bharat Biotech, Hyderabad

C) Biological E Limited, Hyderabad

D) Dr. Reddy's Laboratories, Hyderabad

Answer: C

Explanation: Takeda partnered with Hyderabad-based Biological E Limited to manufacture up to 50 million doses of QDENGA annually in India.

📜 Previous Year Question Style (PYQ)

PYQ 1:

With reference to mosquito-borne viral diseases in India, consider the following statements regarding Dengue:

1. Dengue is caused by a single, unique viral serotype.
2. The primary mosquito vector for dengue transmission is Aedes aegypti.

Which of the statements given above is/are correct?

A) 1 only

B) 2 only

C) Both 1 and 2

D) Neither 1 nor 2

Answer: B

PYQ 2:

Consider the following statements regarding the newly approved dengue vaccine QDENGA (TAK-003):

Which of the above statements are correct?

A) 1 and 2 only

B) 2 and 3 only

C) 1 and 3 only

D) 1, 2, and 3

Answer: C

Explanation: Statements 1 and 3 are correct. Statement 2 is incorrect because QDENGA can be administered regardless of prior dengue exposure, eliminating the need for pre-vaccination screening.

PYQ 3:

Match List-I (Vaccine/Drug Term) with List-II (Biological Characteristic):

List-I:

a. Live-attenuated vaccine b. Tetravalent vaccine c. Chimeric virus d. Serotype

List-II:

Select the correct answer using the code given below:

A) a-2, b-1, c-3, d-4

B) a-1, b-2, c-4, d-3

C) a-2, b-4, c-3, d-1

D) a-3, b-1, c-2, d-4

Answer: A

✍️ Mains Answer Pointers

Question 1 (150 words): Discuss the public health significance of DCGI's approval of the QDENGA vaccine in managing India's seasonal dengue burden.

However, vaccination must complement, rather than replace, traditional vector management, urban sanitation, and disease surveillance under the National Vector Borne Disease Control Programme.

Question 2 (250 words): Analyze the challenges in implementing a national vaccination campaign against dengue in India and suggest strategic measures for effective rollout.

To ensure an effective national strategy, India should pursue a multi-pronged approach:

Phased Integration: Prioritize high-endemic urban hotspots and districts with high hospitalisation rates before universal scaling.
Price Regulation & UIP Entry: Include the vaccine within the Universal Immunization Programme (UIP) or subsidize procurement through tiered pricing models.
Integrated Vector Management: Maintain robust municipal vector control, source reduction, and community awareness, as vaccination alone cannot eliminate transmission.
Real-time Surveillance: Strengthen digital tracking through platforms like U-WIN to monitor coverage, booster requirements, and adverse events.

Combining vaccine technology with systemic urban sanitation will prove decisive in curbing India's dengue epidemic.

⚠️ Examiner Trap

Trap 1: Students often confuse QDENGA (TAK-003) with Dengvaxia. The correct fact is that Dengvaxia required mandatory blood testing to prove prior infection, whereas QDENGA is approved without pre-vaccination screening.
Trap 2: A common wrong assumption is that QDENGA covers only adults. The reality is that the DCGI approved it for individuals aged 4 to 60 years.
Trap 3: Many students miss the regulatory authority details. Always remember that drug and vaccine approvals are granted by the DCGI under CDSCO, not by the Indian Council of Medical Research (ICMR).

🧭 Exam Tip

Prelims Focus: Focus on specific factual details such as the vaccine platform (live-attenuated tetravalent), target age group (4–60 years), lack of pre-screening requirement, two-dose schedule (3 months apart), and the governing regulatory rule (NDCT Rules 2019).
Mains Focus: Frame answers around public health governance, health economics (reducing out-of-pocket expenditure), biotechnology, and the necessity of integrating vaccination with vector control under the National Vector Borne Disease Control Programme.
Interview Angle: Be prepared to discuss whether dengue vaccines should be included in the public Universal Immunization Programme (UIP) versus remaining in the private market, balancing fiscal constraints against public health benefits.
High-Probability Prediction: Expect a statement-based question in Prelims comparing live-attenuated versus mRNA/subunit vaccine platforms, or asking about vector-borne disease control initiatives in India.